Testosterone Undecanoate
FDA-approved product (injectable, intramuscular), marketed as Aveed, Jatenzo, Kyzatrex and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Hypogonadism
- Hypogonadotropic hypogonadism
- Klinefelter's syndrome
- Neoplasm
- Orchitis
- Physiological sexual disorder
- Sexual dysfunction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- 3-oxoandrosten (4) derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Testosterone Undecanoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
NCT04467697 · start 2018-09-18
Registered record
- Registry ID
- NCT04467697
- Conditions
- Hypogonadism, Male
- Interventions
- SOV2012-F1
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2018-09-18
- Completion
- 2020-05-01
- Enrolment
- 155
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism, MaleInterventionSOV2012-F1PhasePhase 3Registry statusCompletedAmbulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men
NCT03868059 · start 2018-04-30
Registered record
- Registry ID
- NCT03868059
- Conditions
- Hypogonadism, Male
- Interventions
- LPCN 1021
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2018-04-30
- Completion
- 2019-02-21
- Enrolment
- 138
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism, MaleInterventionLPCN 1021PhasePhase 3Registry statusCompletedEfficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
NCT03198728 · start 2017-07-05
Registered record
- Registry ID
- NCT03198728
- Conditions
- Hypogonadism, Male
- Interventions
- SOV2012-F1; AndroGel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-07-05
- Completion
- 2020-05-01
- Enrolment
- 314
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism, MaleInterventionSOV2012-F1; AndroGelPhasePhase 3Registry statusCompletedTestosterone Plus Finasteride Treatment After Spinal Cord Injury
NCT02248701 · start 2017-04-27
Registered record
- Registry ID
- NCT02248701
- Conditions
- Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries; Central Nervous System Diseases; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male
- Interventions
- Testosterone Enanthate; Finasteride; Placebo injection; Placebo pill
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2017-04-27
- Completion
- 2021-08-13
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries +7 moreInterventionTestosterone Enanthate; Finasteride; Placebo injection; Placebo pillPhasePhase 2Registry statusTerminatedDosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)
NCT03242408 · start 2017-01
Registered record
- Registry ID
- NCT03242408
- Conditions
- Hypogonadism, Male
- Interventions
- LPCN 1021
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-01
- Completion
- 2017-07
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism, MaleInterventionLPCN 1021PhasePhase 3Registry statusCompletedThe Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
NCT02921386 · start 2016-10
Registered record
- Registry ID
- NCT02921386
- Conditions
- Hypogonadism
- Interventions
- Oral Testosterone Undecanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2016-10
- Completion
- 2017-01-21
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionOral Testosterone UndecanoatePhasePhase 2Registry statusCompletedA Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
NCT02722278 · start 2016-03
Registered record
- Registry ID
- NCT02722278
- Conditions
- Hypogonadism
- Interventions
- Oral Testosterone Undecanoate; Axiron Testosterone Topical Solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-03
- Completion
- 2016-11
- Enrolment
- 222
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionOral Testosterone Undecanoate; Axiron Testosterone Topical SolutionPhasePhase 3Registry statusCompletedTestosterone Therapy in Hypogonadal Men Treated With Opioids
NCT02433730 · start 2015-05-01
Registered record
- Registry ID
- NCT02433730
- Conditions
- Hypogonadism
- Interventions
- Testosterone; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-05-01
- Completion
- 2019-09-01
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone; placeboPhasePhase 4Registry statusCompletedTestosterone-Dependent Effects on Protein Biomarkers From Healthy Males
NCT03541395 · start 2015-03
Registered record
- Registry ID
- NCT03541395
- Conditions
- Hypogonadism, Male
- Interventions
- GnRH antagonist
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2015-03
- Completion
- 2015-06
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism, MaleInterventionGnRH antagonistPhaseNot applicableRegistry statusCompletedTestosterone, Metformin, or Both, for Hypogonadism in Obese Males
NCT02514629 · start 2013-07-04
Registered record
- Registry ID
- NCT02514629
- Conditions
- Hypogonadism; Obesity
- Interventions
- Placebo; Metformin; Testosterone Undecanoate; Metformin + Testosterone Undecanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-07-04
- Completion
- 2016-07-12
- Enrolment
- 107
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism; ObesityInterventionPlacebo; Metformin; Testosterone Undecanoate; Metformin + Testosterone UndecanoatePhasePhase 3Registry statusCompletedTestosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)
NCT01919294 · start 2013-07
Registered record
- Registry ID
- NCT01919294
- Conditions
- Nonalcoholic Steatohepatitis; Hypogonadism
- Interventions
- testosterone undecanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-07
- Completion
- 2017-01-30
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNonalcoholic Steatohepatitis; HypogonadismInterventiontestosterone undecanoatePhasePhase 2Registry statusCompletedOral Testosterone for the Treatment of Hypogonadism
NCT01717768 · start 2012-10
Registered record
- Registry ID
- NCT01717768
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2014-12
- Enrolment
- 130
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTSX-002PhasePhase 2Registry statusCompletedOpen-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
NCT01699178 · start 2012-08
Registered record
- Registry ID
- NCT01699178
- Conditions
- Male Hypogonadism
- Interventions
- Oral testosterone undecanoate; Transdermal testosterone gel (AndroGel)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-08
- Completion
- 2014-04
- Enrolment
- 182
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMale HypogonadismInterventionOral testosterone undecanoate; Transdermal testosterone gel (AndroGel)PhasePhase 3Registry statusCompletedEffectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women
NCT01724658 · start 2012-06
Registered record
- Registry ID
- NCT01724658
- Conditions
- Female Sexual Dysfunction
- Interventions
- Testosterone undecanoate; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-06
- Completion
- 2013-05
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFemale Sexual DysfunctionInterventionTestosterone undecanoate; placeboPhasePhase 2Registry statusCompletedOral Testosterone for Fatigue in Male Multiple Sclerosis Patients
NCT01516554 · start 2012-02
Registered record
- Registry ID
- NCT01516554
- Conditions
- Multiple Sclerosis; Fatigue
- Interventions
- Testosterone undecanoate; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2012-02
- Completion
- 2014-07
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple Sclerosis; FatigueInterventionTestosterone undecanoate; placeboPhasePhase 2Registry statusTerminated